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Background: Tumor metastasis is responsible for 90% of cancer-related deaths. Recently, a strong link between
microRNA dysregulation and human cancers has been established. However, the molecular mechanisms through
which microRNAs regulate metastasis and cancer progression remain unclear.
Methods: We analyzed the reciprocal expression regulation of miR-31 and SOX4 in esophageal squamous and
adenocarcinoma cell lines by qRT-PCR and Western blotting using overexpression and shRNA knock-down approaches.
Furthermore, methylation studies were used to assess epigenetic regulation of expression. Functionally, we determined
the cellular consequences using migration and invasion assays, as well as proliferation assays. Immunoprecipitation and
ChIP were used to identify complex formation of SOX4 and co-repressor components.
Results: Here, we report that SOX4 promotes esophageal tumor cell proliferation and invasion by silencing miR-31
via activation and stabilization of a co-repressor complex with EZH2 and HDAC3. We demonstrate that miR-31 is
significantly decreased in invasive esophageal cancer cells, while upregulation of miR-31 inhibits growth, migration and
invasion of esophageal adenocarcinoma (EAC) and squamous cell carcinoma (ESCC) cell lines. miR-31, in turn, targets
SOX4 for degradation by directly binding to its 3′-UTR. Additionally, miR-31 regulates EZH2 and HDAC3 indirectly.
SOX4, EZH2 and HDAC3 levels inversely correlate with miR-31 expression in ESCC cell lines. Ectopic expression of
miR-31 in ESCC and EAC cell lines leads to down regulation of SOX4, EZH2 and HDAC3. Conversely, pharmacologic
and genetic inhibition of SOX4 and EZH2 restore miR-31 expression. We show that SOX4, EZH2 and HDAC3 form a
co-repressor complex that binds to the miR-31 promoter, repressing miR-31 through an epigenetic mark by H3K27me3
and by histone acetylation. Clinically, when compared to normal adjacent tissues, esophageal tumor samples show
upregulation of SOX4, EZH2, and HDAC3, and EZH2 expression is significantly increased in metastatic ESCC tissues.
Conclusions: Thus, we identified a novel molecular mechanism by which the SOX4, EZH2 and miR-31 circuit promotes
tumor progression and potential therapeutic targets for invasive esophageal carcinomas.
Keywords: Esophageal cancer, Oncogene, MicroRNA, miR-31, EZH2, SOX4, HDAC3, EpigeneticsBackground
MicroRNAs (miRNAs) are a class of highly-conserved,
noncoding 18-25- nucleotide RNAs that function as nega-
tive regulators of gene expression at the post-transcription
level, binding to the 3′-untranslated region (3′-UTR) of
mRNAs transcripts and targeting them for degradation
[1]. Though implicated in carcinogenesis, it is not clear* Correspondence: claudia.andl@vanderbilt.edu
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unless otherwise stated.how miRNAs promote tumorigenesis and metastasis or
what networks regulate miRNAs expression. miRNA
expression is commonly dysregulated in human cancers,
[2,3] including esophageal cancers [4].
miR-31 expression is altered in multiple human cancers.
Depending on the cellular context, miR-31 may be up- or
downregulated, acting as an oncogene or tumor suppres-
sor, respectively. Overexpression of miR-31 has been
linked to disease progression in colorectal cancer [5],
head-and-neck squamous cell carcinoma (HNSCC) [6]
and lung cancer [7]. miR-31 is downregulated in certain
T-cell leukemias [8], breast cancer [9,10], melanoma [11],entral. This is an Open Access article distributed under the terms of the Creative
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tion and loss of miR-31 in esophageal adenocarcinoma
(EAC) correlates with poor patient prognosis [14-16].
Additionally, miR-31 expression is reduced in EAC
patients with poor histomorphologic response to neoadju-
vant chemoradiation therapy [17]. Conversely, miR-31 is
upregulated in serum and tissue samples of esophageal
squamous cell carcinoma (ESCC), with expression correl-
ating to staging [18]. Yet, in another ESCC cohort miR-31
expression was decreased, and low miR-31 expression cor-
related with poorly differentiated tumors and decreased
survival [19]. These reports emphasize the complexity of
miR-31-associated phenotypes and the need to better
define miR-31 targets, as well as pathways regulating miR-
31 expression in different cancers.
SOX4 is a member of the highly conserved SoxC
(SRY-related high-motility group box) transcription factors
family, which contains two other members, SOX11 and
SOX12 [20]. SOX4 is a putative stem cell marker that plays
a crucial role during cell fate determination [21,22]. SOX4-
deficient mice suffer from multiple developmental defects,
dying at embryonic day 14, secondary to ventricular out-
flow tract malformation [23]. During embryogenesis, SoxC
members are highly expressed, helping to maintain survival
of pluripotent mesenchymal and neural progenitor cells
[24]. In adults, expression of SOX4 is restricted to certain
cell types, including hematopoietic stem cells, mammary
stem cells and hair follicle stem cells [25-27].
Meta-analysis has identified SOX4 as one of the 64
genes that constitute a general signature in all human
cancers, and genome wide promoter analysis has shown
that SOX4 regulates the transcription of genes involved
in TGF-β, Wnt, Hedgehog, and Notch pathways and
components of miRNA processing machinery such as
Dicer, Argonaute 1 and RNA Helicase A [28,29]. SOX4
induces EMT and breast cancer progression by cooperat-
ing with oncogenic Ras. More recent work shows that
SOX4 induces EMT via the polycomb epigenetic regula-
tor EZH2 [30]. miRNAs, such as miR-335, are known to
target SOX4, suppressing metastasis and migration in
breast cancer [3].
Polycomb group proteins have been linked to tumor
progression in many cancers. The polycomb proteins can
form at least two complexes: polycomb-repressive com-
plexes 1 and 2 (PRC1 and PRC2). PRC2 contains three core
proteins, EZH2, SUZ12, and EED. The histone methyl-
transferase EZH2 (enhancer of zeste homolog 2) epigeneti-
cally regulates genes involved in cell fate determination.
Specifically, EZH2 trimethylates nucleosomal histone H3 at
lysine 27 (H3K27me3). The H3K27me3 mark is associated
with gene silencing and often found in the promoter of
developmental genes [31,32]. However, it is unclear how
EZH2 is recruited to the promoters it targets. Recent
studies have shown that EZH2 interacts with varioustranscription factors such as androgen receptor (AR),
GATA4, RORα and STAT3 and may directly activate or
repress these genes independent of the H3K27me3 mark or
chromatin modification [33-36]. With respect to miRNAs,
prior work demonstrates that EZH2 interacts with AR to
silence miR-31 in prostate cancers, and C-MYC recruits
EZH2 to the miR-29 promoter in B-cell lymphomas [37].
EZH2 is upregulated in multiple cancers, promoting
invasion and metastasis [38-40]. Genetic and epigenetic
loss of miR-31 is associated with EZH2 overexpression in
melanoma [11], suggesting that miR-31 directly or indir-
ectly regulates EZH2 expression. Interestingly, studies
show that polycomb complexes silence the CDKN2A and
CDKN2B loci, which encode the tumor suppressors p14
(ARF), p15 (INK4B) and p16 (INK4A) [41] and contain
the MIR31HG locus on chromosome 9 [42]. In line with
this observation, Yamagishi et al. reported that PRC2
binds the miR-31 coding region and directly represses
transcription of miR-31 in adult T-cell leukemia [8]. SOX4
positively regulates EZH2, indicating a potential functional
link between miR-31, EZH2 and SOX4.
The roles of SOX4, HDAC3 and EZH2 in microRNA
regulation are largely unknown and have been poorly
defined so far. In this study, we explore the role of SOX4
and EZH2 in miR-31 repression and the contribution of
miR-31 to survival, migration and invasion of aggressive
esophageal cancers cells. We identify SOX4 as a direct
target of miR-31. Expression of miR-31 inhibits SOX4,
EZH2 and HDAC3 expression. We show that miR-31 is
repressed in invasive esophageal cancers cell lines and
that miR-31 levels inversely correlate with SOX4, EZH2
and HDAC3 expression. Co-immunoprecipitation demon-
strates that SOX4 interacts with EZH2 and that HDAC3
may be important to bridge this interaction. We show that
EZH2 and HDAC3 bind to the miR-31 promoter using
chromatin immunoprecipitation. Altogether, our results
identify a feed-forward loop that leads to the activation of
SOX4, which in turn up-regulates and binds to EZH2,
cooperating with HDAC3 to repress the miR-31 promoter
and advance esophageal tumorigenesis.
Results
miR-31 expression is downregulated in invasive
esophageal cancer cells
To investigate the role of miR-31 in esophageal cancers,
we examined the expression of miR-31 in ESCC, EAC
and Barrett’s esophagus cell lines of differing invasive
potential (Figure 1). Comparing esophageal squamous
cell carcinoma cell lines, TE11 is less motile than TE8
and displays an epithelial phenotype (Figure 1A). The
esophageal adenocarcinoma cell lines OE33 and FLO1
differ in that FLO1 is more mesenchymal and therefore
more motile than the OE33 (Figure 1B). After miR-200a
and 200b, which are known for their roles in EMT, miR-
Figure 1 miR-31 is downregulated in invasive esophageal cancer cells. (A, B) Morphologic, migration and invasive capability of two ESCC
cells lines and two EAC cell lines were analyzed by bright field microscopy and Boyden chamber transwell assays. (C) Fold change in expression
of 18 miRNAs between the invasive EAC cell line FLO1 and non-invasive cell line OE33. (D-F) Quantitative RT-PCR for relative expression of
miR-31. miR-31 expression was normalized to RNU6. (D) High expression of miR-31 in non-invasive ESCC TE11 cells versus invasive TE8 cells.
(E) Higher expression in the CP-A cell line compared to CP-B and (F) non-invasive EAC OE33 compared with FLO1. Means ± SD from at least three
biological replicates.
Koumangoye et al. Molecular Cancer  (2015) 14:24 Page 3 of 1631 was the most downregulated miRNA in invasive
FLO1 cells compared to their less invasive OE33 coun-
terparts by qPCR screen (Figure 1C). Similarly, miR-31
downregulation was observed in TE8 ESCC cell lines
compared to TE11 (Figure 1D). Likewise, miR-31 expres-
sion was higher in non-invasive cell lines such as the
benign Barrett’s esophagus cell line CP-A compared to the
metaplastic CP-B cell line (Figure 1E). Furthermore, we
confirmed the elevated miR-31 expression in OE33 cells,
which have an epithelial phenotype, compared to FLO1
cells (Figure 1F). Next, to focus on the biological signifi-
cance and regulatory mechanisms of miR-31 expression in
invasive adenocarcinoma and squamous cell carcinoma,
we expressed miR-31 in invasive ESCC and EAC cell lines
and analyzed the effects on cell migration and invasion.
miR-31 suppresses migration and invasion of aggressive
ESCC and EAC cells
To examine the functional contribution of miR-31 in
aggressive esophageal cancer, we transfected TE8 and
FLO1 cells with vectors containing the precursor of
miR-31 or an empty vector control. Ectopic expression
of precursor and mature miR-31 in the respective cell
lines was tested by quantitative RT-PCR (Figure 2A). InBoyden chamber migration and invasion assays, pre-
cursor miR-31 transfection significantly decreased cell
migration and invasion in TE8 and FLO1 cells (Figure 2B,
C, respectively). miR-31 expression had no significant
effect on proliferation in TE8 cells and did not alter
the number of colonies in colony formation assays
(Figure 2D, E). In FLO1 cells, however, miR-31 sup-
pressed proliferation and colony formation (Figure 2D,
E, respectively), indicating miR-31 regulates esophageal
carcinoma cell growth in some cell lines. These data
suggest that miR-31 suppresses esophageal cancer cell
motility and invasiveness, but cell growth depending on
the cellular context.
miR-31 is epigenetically repressed in invasive esophageal
cancer cells
Prior studies report that miR-31 expression is epigeneti-
cally silenced through promoter hypermethylation at CpG
islands, as well as polycomb-mediated histone methylation
[8,11]. We therefore speculated that loss of miR-31 in
invasive esophageal cancer cells could be mediated, in
part, by DNA and histone methylation. To determine the
effect of PRC2 on miR-31 expression, we utilized the
PRC2 inhibitor, 3-deazaneplanocin (DZNep). DZNep
Figure 2 (See legend on next page.)
Koumangoye et al. Molecular Cancer  (2015) 14:24 Page 4 of 16
(See figure on previous page.)
Figure 2 Ectopic expression of miR-31 suppresses migration and invasion of ESCC and EAC cell lines. TE8 and FLO1 cells were transfected
with pre-miR-31 containing vector (grey bars) or empty vector control (black bars). (A) Overexpression of miR-31 was verified by qRT-PCR. Pre-mature
miR-31 expression was normalized to GAPDH and mature miR-31 expression was normalized to RNU6. (B) Cell migration was measured 24 hours
post-transfection using Boyden chambers. (C) Cell invasion was measured 24 hours post-transfection using Matrigel-coated Boyden chambers.
(D) Cell viability was measured using the WST-1 assay. (E) Cell growth was evaluated by colony formation assay and measured on the Oxford Optronix
Gelcount. Results are means ± SD from at least three biological replicates.
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EZH2 expression and caused a dose-dependent increase
in miR-31 expression in both of our invasive cell lines
(Figure 3A, B, respectively). DZNep treatment also led to
a decrease in SOX4 protein level in FLO1 cells (Figure 3A).
SOX4 was recently shown to upregulate EZH2 expression
[30]. Using Western blot and qRT-PCR, we evaluated the
effect of a pan-HDAC inhibitor (SAHA) on miR-31
expression. We found that SAHA led to a decrease in
HDAC3, EZH2 and EZH1 protein levels in TE8 and FLO1
cells (Figure 3C). Most importantly, miR-31 expression
was significantly upregulated in both cell lines following
SAHA treatment (Figure 3D). To test whether promoter
methylation at CpG islands was involved in miR-31 silen-
cing, we used the DNA methylation inhibitor 5′AZA-
Deoxy-Cytidine (AZA). Treatment with AZA significantly
increased the expression of miR-31 in TE8 cells and to a
lesser extent in FLO1 cells (Figure 3E and F). These data
suggest that PRC2, HDAC and DNA methylation are in-
volved in miR-31 epigenetic silencing.
miR-31 directly targets SOX4 and indirectly targets EZH2
and HDAC3
A study by Asangani et al. recently showed that genetic
and epigenetic loss of miR-31 leads to a feed forward
upregulation of EZH2 [11]. However, no mechanism was
proposed. Previously, EZH2 was reported to interact
with HDAC3 to repress miR-29 in lymphomas [37].
More recent work shows that SOX4 binds to the EZH2
promoter, thereby upregulating EZH2 expression [30].
We hypothesized that SOX4 initiates the feed forward
activation of EZH2, which in turn represses miR-31. Ana-
lysis of the SOX4 3′-UTR using microrna.org (maintained
at cBio, the Computational Biology Center at Memorial
Sloan-Kettering Cancer Center) predicted a miR-31 bind-
ing site (Figure 4A). A sequence alignment search showed
that the miR-31 target sequence in the SOX4 3′-UTR is
conserved in humans and most great apes (Figure 4A).
To test whether SOX4 is regulated by miR-31 through
direct binding to its 3′UTR, we used psiCHECK2
SOX4 full length 3′-UTR plasmid (WT) [3], and con-
structed two derivatives, SOX4 WT 3′-UTR oligo plas-
mid (WT OLIGO) and SOX4 mutant 3′-UTR oligo
plasmid (MUT OLIGO) (Figure 4A). The WT OLIGO
plasmid contained a 71-nucleotide region including the
miR-31 target sequence. In the SOX4 mutant 3′-UTR(MUT OLIGO), 4 nucleotides in the seed sequence
were mutated [3]. When co-transfected into HEK-293
cells, the luciferase reporter, SOX4 WT 3′-UTR and
miR-31 plasmid showed reduced luciferase activity com-
pared to co-transfection with miR-31 empty control vector
(Figure 4B). This suppressive effect was reversed by the
four-nucleotide substitution in the miR-31 binding se-
quence. Similarly, the suppressive effect of miR-31 on the
SOX4 3′-UTR activity was observed in the esophageal
tumor cell lines, TE8 and FLO1 (Figure 4B). In line with
these results, overexpression of miR-31 in FLO1 cells
suppressed the expression of SOX4 at both the protein
(Figure 4C) and mRNA level (Figure 4D). As previously
reported [11], our data confirm that miR-31 inhibits EZH2
expression (Figure 4C and D) whereas EZH1 expression
was unchanged. Interestingly, miR-31 decreased HDAC3
on protein (Figure 4C) and mRNA levels (Figure 4D).
However, target prediction algorithms do not detect any
putative binding site for miR-31 in the 5′UTR, 3′UTR or
coding sequence of HDAC3. Taken together, these results
demonstrate that SOX4 is a direct target of miR-31, while
EZH2 and HDAC3 are indirect targets.
To analyze the regulation of miR-31, EZH2, EZH1 and
HDAC3 by SOX4, we chose TE11 cells, which express
low SOX4 and EZH2 levels, had high expression of miR-
31 as a model. Ectopic expression of SOX4 in TE11 cells
(Figure 4E) decreased miR-31 expression, although this
was not statistically significant (Figure 4F). Additionally, we
observed that SOX4 induced EZH2 expression (Figure 4F)
as previously reported [30], but not EZH1. HDAC3 expres-
sion increased as well. Consistent with this observation,
overexpression of EZH2 in TE11 cells (Figure 4G) led to a
significant decrease in miR-31 expression (Figure 4H).
Interestingly, EZH2 induced SOX4 expression by more
than a 2-fold (Figure 4H), suggesting that not only does
SOX4 regulate EZH2, but EZH2 also regulates SOX4
thereby potentially repressing miR-31 and/or other miR-
NAs and transcription factors.
Depletion of SOX4 suppresses growth, migration and
invasion of esophageal cancer cells
Based on the observation that miR-31 targets both
SOX4 and EZH2 and given that SOX4 binds to the
EZH2 promoter to activate its transcription, we exam-
ined whether SOX4 leads to feed forward activation of
EZH2, and subsequent miR-31 silencing. TE8 and FLO1
Figure 3 (See legend on next page.)
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Figure 3 miR-31 is epigenetically repressed in invasive esophageal cancer cells. TE8 and FLO1 cells were treated at indicated concentrations
with Polycomb/EZH2 inhibitor (DZNep), Histone deacetylase inhibitor (SAHA) and DNA methyl-transferase inhibitors (AZA). (A) DZNep treatment for
72 hours dose-dependently inhibits EZH2 and EZH1 in FLO1 and TE8 cells as shown by western blotting. (B) qRT-PCR analysis of miR-31 expression in
TE8 and FLO1 cells treated with DZNep for 72 hours. (C) SAHA treatment for 48 hours inhibits HDAC3, EZH2 and EZH1 in TE8 and FLO1 cells in a
dose-dependent manner. (D) qRT-PCR analysis of miR-31 expression in TE8 and FLO1 cells treated with SAHA for 48 hours. (E-F) qRT-PCR analysis of
miR-31 expression in TE8 and FLO1 cells treated with 5-aza-deoxycytidine (AZA) for 72 hours. miR-31 expression was normalized to RNU6. Results are
means ± SD from at least three biological replicates, ANOVA was used for statistical analysis.
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showed the lowest expression level of miR-31. SOX4
knockdown (Figure 5A) using shRNA led to significant
upregulation of miR-31 in TE8 and FLO1 cells, while
miR-191 and miR-423-5p, used as controls, did not show
any significant change (Figure 5B and C). We next inves-
tigated if loss of SOX4 functionally mimics overexpres-
sion of miR-31 in esophageal cancer cells. To assess the
role of SOX4, we studied the migratory and invasive
potential of TE8 and FLO1 cells following SOX4 knock-
down with shRNA. Suppression of SOX4 inhibited trans-
well migration (Figure 5D and E) and invasion through
Matrigel-coated Boyden chambers (Figure 5F and G) in
TE8 and FLO1 cells. SOX4 knockdown cells also showed
a significant reduction in proliferation (Figure 5H and I).
Taken together, these data implicate SOX4 as a key medi-
ator of the tumor-suppressive effects of miR-31 in this
system.
SOX4, HDAC3 and EZH2 form a co-repressor complex to
inhibit miR-31 expression
PRC2 is known to recruit DNA methyl-transferases
(DNMTs), HDACs and other chromatin modifying en-
zymes to repress the transcription of developmental genes
[43]. Because SOX4 was recently shown to interact with
other transcription factors, we tested whether SOX4 forms
a co-repressor complex with EZH2 and HDAC3 to silence
miR-31 expression. Using anti-SOX4 antibody for co-
immunoprecipitation, cell lysates from TE8 (Figure 6A)
and FLO1 cells (Figure 6B) showed interactions between
SOX4 and EZH2, HDAC3 and H3K27me3 (Figure 6A, B).
We next performed co-immunoprecipitation assays
with anti-EZH2 antibody and showed that EZH2
equally interacts with SOX4 (Figure 6A, B). Immuno-
precipitates obtained with EZH2 antibody detected also
HDAC3, H3K27me3, and Suz12 (Figure 6A, B). To test
whether HDAC3 interacts with SOX4 and EZH2,
HDAC3-antibody was used for pull down. Lysates immu-
noprecipitated with HDAC3-specific antibody contained
EZH2, SOX4, H3K27me3 in TE8 cells (Figure 6A), but
only a faint band of EZH2 in FLO1 cells (Figure 6B).
Suz12 was not detected after pull-down with HDAC3-
specific antibody in either cell line.
Finally, we tested whether SOX4, EZH2 and HDAC3
tethered to the miR-31 promoter. Previous reports identifyCpG islands and histone trimethylation mark sites up-
stream of the miR-31 promoter [8]. Therefore, we tested
whether SOX4, EZH2 and HDAC3 bind to those regions.
ChIP analysis denoted H3K27me3 and HDAC3 enrich-
ment in regions upstream of miR-31 (Figure 6C). How-
ever, we were unable to detect SOX4 at miR-31 promoter
regions (data not shown). HDAC3 and H3K27me3 were
equally enriched at the MYT1 promoter, which was used
as a positive control as EZH2 has been shown to bind
and regulate MYT1 promoter activity [44]. We conclude
that SOX4, HDAC3 and EZH2 function as a potential
co-repressor complex to silence miR-31.
SOX4, EZH2 and HDAC3 inversely correlate with miR-31
expression in invasive esophageal cancer cells
To determine the expression of the complex-forming
partners, SOX4, EZH2 and HDAC3, in esophageal can-
cer cell lines and tissues, we used qRT-PCR. We profiled
SOX4, EZH2 and HDAC3 in ESCC (Figure 7A) and
EAC (data not shown) cell lines and found a strong,
inverse correlation between miR-31 and expression of
SOX4, EZH2 and HDAC3 in invasive cancers of both
histologies. Probing various publicly available datasets
(GSE20347, GSE47404, GSE13937) to assess the expres-
sion of SOX4, EZH2 and HDAC3 in primary esophageal
squamous and adenocarcinoma samples, we found SOX4
and EZH2 to be significantly upregulated in ESCC
tumor samples (GSE20347), compared to normal tis-
sues (Figure 7B). In another ESCC dataset (GSE47404),
only EZH2 expression (P value = 0.008) was significantly
upregulated in metastatic compared to non-metastatic
patients. In EAC dataset (GSE13937), we found that
SOX4 (P value = 0.003) and HDAC3 (P value = 0.042)
were increased in tumor samples compared to adjacent
normal tissues (Figure 7C). Taken together, these data
identify a molecular circuit where SOX4, EZH2 and
HDAC3 target miR-31 to promote esophageal malignancy.
Inversely, in non-invasive tumor cells miR-31 targets
SOX4, EZH2 and HDAC3 by direct and indirect means to
inhibit tumor cell invasion (Figure 7D).
Discussion
Differential microRNAs expression has been linked to
tumor initiation and progression. Depending on cellular
context, microRNA expression in tumors may be increased
Figure 4 (See legend on next page.)
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Figure 4 miR-31 directly targets SOX4 and indirectly targets EZH2 and HDAC3. (A) Computational analysis revealed one miR-31 binding site
in the 3′UTR of SOX4. The upper panel shows the region containing the miR-31 binding site. The mutated SOX4 3′UTR seed region is indicated. A
SOX4 3′UTR fragment containing wild type (WT OLIGO) or mutant (MUT OLIGO) of the miR-31-binding sequence was cloned into the downstream of
the luciferase reporter gene. The lower panel shows the nucleotide sequence alignment of the predicted miR-31 binding site in the 3′UTR of SOX4 of
six species. (B) HEK293, TE8 and FLO1 cells were co-transfected with psiCHECK-2 dual Renilla/Firefly luciferase plasmid containing either wild-type,
wild-type oligo or mutant oligo of SOX4 3′UTR (indicated as WT, WT OLIGO and MUT OLIGO) with either pBABE empty vector control or pBABE-miR-31
vector. Luciferase activity was determined 48 hrs after transfection. (C) TE8 and FLO1 cells were transfected with miR-31 vector or empty vector
control and cell lysates were analyzed after 72 hrs for SOX4, EZH2, EZH1 and HDAC3 by western blotting. α-tubulin was used as an internal
control. (D) qRT-PCR analysis of SOX4, EZH2, EZH1 and HDAC expression in TE8 and FLO1 cells transfected with miR-31 or empty vector
control. (E, F) qRT-PCR analysis of TE11 cells transfected with SOX4 or empty vector control. (G, H) qRT-PCR analysis of TE11 cells transfected
with EZH2 or empty vector control. miR-31 expression was normalized to RNU6 and SOX4, EZH2, EZH1 and HDAC3 were normalized to
GAPDH. Results are means ± SD from at least three biological replicates.
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moters or suppressors, respectively [2]. Moreover, multiple
microRNAs have been shown to promote or inhibit metas-
tasis [3,45]. Because metastasis is responsible for more than
90% of cancers-related deaths, it is important to define mo-
lecular mechanisms by which microRNAs regulate metas-
tasis and define new therapeutic targets. Studies on the role
of miR-31 in esophageal tumors have produced conflicting
results [16,18,19,46]. Hence, it is important to define not
only the molecular pathways regulated by miR-31 but also
the factors regulating miR-31 expression and functions in
various tissues and cancers. The lack of consistency in the
literature with respect to miR-31 expression in esophageal
cancer may be due to platform choice or normalization
methods. Variability may also result due to the limited
number of patients in each study. Here, we show downreg-
ulation of miR-31 in invasive and aggressive esophageal
cancer cells. miR-31 has a known role in prostate cancer
and melanoma, suppressing key cell cycle regulators and
pro-oncogenic genes such as CDK1, E2F2, EXO1, FOXM1,
MCM2, Src or MET [11]. We show that miR-31 signifi-
cantly suppresses migration and invasion in vitro in both
aggressive esophageal adenocarcinoma and squamous cell
carcinoma. Ectopic expression of miR-31 did not signifi-
cantly affect tumor cell proliferation, causing only a mar-
ginal decrease in colony formation in the adenocarcinoma
cell line FLO1. Interestingly, Valastyan et al. also reported
that miR-31 promoted metastasis but not cell proliferation
in breast cancer [9]. A number of studies argue that
epithelial-mesenchymal transition (EMT) plays a crucial
role in cancer metastasis and progression, and loss of miR-
200 family members drives EMT in multiple cancers
[47,48]. We examined expression of EMT markers in miR-
31-overexpressing cell lines but found no significant alter-
ations (data not shown). We conclude that miR-31 is not a
strong inhibitor of EMT.
Several mechanisms could contribute to aberrant miR-
31 expression in cancer. Based on data demonstrating
epigenetic repression of miR-31 expression by DNA
methylation and EZH2-mediated H3K27me3 epigenetic
mark in melanoma, leukemia and prostate cancer [8,11],we examined the role of epigenetic regulation of miR-31 in
invasive esophageal cancer. Our results indicate that DNA
methylation and Polycomb-mediated histone methylation
both contribute to miR-31 silencing, since treatment with
the EZH2 inhibitor, DZNep, and the DNMT inhibitor,
AZA, enhanced miR-31 expression. Additionally, we show
for the first time that histone deacetylation contributes to
miR-31 silencing as treatment with the pan-HDAC inhibi-
tor SAHA restored miR-31 expression. This is in line with
recent observations that EZH2 interacts with HDAC3 to
downregulate miR-29 [37] and that EZH2 can interact with
DNMT to control DNA methylation [49]. Therefore, we
propose a key role for Polycomb/EZH2, HDAC and
DNMT for survival and metastasis of esophageal cancers.
Recent work argues that SOX4 is a master regulator of
EMT and cell invasion through its binding to the EZH2
promoter, inducing EZH2 transcription [30]. Our results
indicate that miR-31 down-regulates SOX4 by binding
to its 3′-UTR in EAC and ESCC cells. Consistent with
previous reports [8,11], we found that miR-31 negatively
regulates EZH2 as well. Furthermore, we observed a sig-
nificant decrease in HDAC3 expression with miR-31
overexpression. We, therefore, propose that one under-
lying mechanism by which miR-31 suppresses tumor cell
invasion is by directly targeting SOX4 and indirectly
targeting EZH2 and HDAC3. Notably, overexpression of
SOX4 is observed in a variety of human cancers [21]. Loss
of SOX4 led to a significant increase in miR-31 expression
and strongly inhibited tumor cells proliferation, migration
and invasion. Additional studies will aim to identify a sub-
set of patients with concomitant high SOX4, EZH2 and
HDAC3 and low miR-31 to demonstrate the mechanistic
and clinical correlation between these pathways.
Multiple reports show that the polycomb PRC2/EZH2
interacts with HDAC to repress the transcription of CDH1
[38]. Moreover, MYC was recently shown to interact with
EZH2 and HDAC3 to repress miR-29 in lymphomas [37].
However, it is not clear how PRC2/EZH2 is recruited to
the promoter of specific genes. Similarly, SOX4 has been
shown to interact with multiple transcription factors.
Despite the fact that our computational analysis did not
Figure 5 (See legend on next page.)
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Figure 5 SOX4 knockdown suppresses migration, invasion and growth of invasive esophageal cancer cells. TE8 and FLO1 cells were
transfected with non-targeting shRNA control or shSOX4. (A) SOX4 protein expression was analyzed by Western blotting. (B, C) miR-31 expression
in response to SOX4 knockdown was measured by qRT-PCR, miR-191 and miR-423-5p were used as controls. miR-31, miR-191, miR-423-5p expression
was normalized to RNU6. (D, E) Cell migration was measured using Boyden chamber transwell assays 24 hour post-transfection. (F, G) Invasion
was measured by Marigel-coated transwell assays 24 hour post-transfection. (H, I) Cell viability was evaluated using the WST-1 assay. Results are
means ± SD from at least three biological replicates.
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miR-31 promoter, co-IP assays show that SOX4 interacts
with EZH2 and HDAC3. Based on the ChIP experiments,
we propose that EZH2 and HDAC3 bind to a similar
region on the miR-31 promoter, confirming that histone
methylation and histone deacetylation contribute to miR-
31 repression. It is also possible that other molecules such
as PRC2-interacting YY1 or the SOX4-interracting protein
GATA4 mediate SOX4 recruitment to the DNA. Future
studies are needed to confirm such possibilities.
Conclusions
Taken together, our data identify a molecular circuit where
SOX4, EZH2 and HDAC3 cooperate to repress miR-31.
This may lead to tumor progression and the metastasis
of EAC and ESCC; SOX4, EZH2, HDAC3 and miR-31
emerge as potential therapeutic targets.
Materials and methods
Cell lines
The squamous cell carcinoma cell lines TE8, TE1, TE11,
TE7, TE12, TE2, TE3, TE5 and TE9 were developed and
characterized by Kuroki et al. [50]. OE33 and FLO1 were
established by Dr. David Beer (University of Michigan).
HEK293T, CP-A and CP-B were purchased from American
Type Culture Collection (ATCC). KYSE140, KYSE180,
KYSE150, KYSE520, KYSE70 were developed and charac-
terized by Shimada et al. [51]. All cells were cultured at
37°C in 5% CO2.
Chemicals and antibodies
Suberoyl anilide hydroxamic acid (SAHA, a pan-HDAC
inhibitor) and 3-Deazaneplanocin A (DZNep, a poly-
comb EZH2 subunit inhibitor) were purchased from
Millipore, Temecula, CA. The DNA methylation inhibi-
tor 5-AZA-Cytidine (AZA) was from Sigma, St. Louis,
MO. Cells were treated with indicated concentration
and incubated for 72 hours before harvesting. Agarose
A/G plus is from Santa Cruz. The following antibodies
were used as primary antibodies: SOX4 (Santa Cruz;
1:1000); EZH2 (BD; 1:4000); HDAC3 (Millipore; 1:4000);
total histone H3 (Abcam; 1:5000); Tri-methylated his-
tone H3 H3K27me3 (Millipore; 1:3000); SUZ12 (Santa
Cruz; 1:1,000); EZH1 (Santa Cruz; 1:1,000); β-tubulin
(Sigma-Aldrich; 1:5,000).Oligonucleotides and plasmids
The pBABE-miR-31 plasmid (Plasmid#26088), pWPXL-
SOX4 (plasmid#36984), pCMVHA-hEZH2 (plasmid#24
230), Psicheck2 SOX4 full-length 3′UTR (Plasmid#26989)
were purchased from Addgene (Cambridge, MA).
A 71 bp WT fragment of the SOX4 3′UTR (SOX4 WT
OLIGO) was created by overlapping extension PCR and
cloned between the XhoI and NotI site of the psicheck2
plasmid. Similarly, the mutant construct of SOX4 3′UTR
(SOX4 Mutant OLIGO) which carried a substitution of
four nucleotides within the core seed sequence of miR-31,
was carried out using overlapping extension PCR and
cloned between the XhoI and NotI site of the psicheck2
plasmid.
The two set of plasmids containing shRNA specific to
SOX4 and EZH2 were purchased from OriGene (Rock-
ville, MD).
Primers used for SOX4, forward: 5′-AGCGACAAG
ATCCCTTTCATTC-3′, reverse: 5′-CGTTGCCGGACT
TCACCTT-3′; EZH2, forward: 5′-GTACACGGGGAT
AGAGAATGTGG-3′, reverse: 5′GGTGGGCGGCTTT
CTTTATCA-3′, for EZH1, forward: 5′-ATGCGACTTC
GACAACTTAAACG-3′, reverse: 5′-GGCTTCATTGA
CTGAACAGGTT-3′, HDAC3, forward: 5′-CCTGGCA
TTGACCCATAGCC-3′, reverse: 5′-CTCTTGGTGAAG
CCTTGCATA-3′, GAPDH, forward: 5′-GCGACACCC
ACTCCTCCAC-3′, reverse: 5′-TCCACCACCCTGTTG
CTGTAG-3′.
3′UTR Luciferase Reporter assays
HEK293, TE8 and FLO1 cells were plated in triplicate in a
24 well plate. One day after plating, cells were transfected
with the dual Renilla and Firefly luciferase reporter
plasmid (psiCHECK-2) containing the full length 3′UTR
of SOX4 (plasmid# 26989), the short WT oligo or mutant
oligo along with a pBABE-miR-31 or pBABE Empty
Vector expressing plasmid using FuGene HD (Promega).
48 hr post-transfection, cells were lysed using 1X passive
lysis buffer and lysates were analyzed using the Dual-Glo
Luciferase Reporter Assay System (Promega) on the
Synergy4 multi-mode microplate reader (BioTeK).
Quantitative real time PCR
Total RNA was isolated from cells with Qiazol reagent
(Qiagen) and reverse transcribed into cDNA using the
miRNeasy mini kit and miScript miRNA Reverse
Figure 6 SOX4 interacts with EZH2 and HDAC3. (A) TE8 cell lysates were immunoprecipitated with SOX4, EZH2, HDAC3 or IgG control antibodies
and immunoblots were probed for indicated antibodies. (B) FLO1 cell lysates were pulled-down with SOX4, EZH2, HDAC3 antibody or IgG control and
immunoblots were probed for indicated antibodies. (C) Quantitative ChIP assay showing H3K27me3, and HDAC3 enrichment on the proximal and
distal promoters regions of miR-31 and its host genes MIR31HG.
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according to the manufacturer’s instructions (Applied
Biosystems).Proliferation assay
WST-1 reagent (Roche) was used according to manufac-
turers’ protocols to assess cell viability.
Figure 7 (See legend on next page.)
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Figure 7 SOX4, EZH2 and HDAC3 are upregulated and inversely correlate with miR-31 in esophageal cancers. (A) qRT-PCR of SOX4,
EZH2, EZH1. HDAC3 and miR-31 in 16 ESCC cell lines. Insert: correlation between mRNA expression of SOX4, EZH2, EZH1, HDAC3 and miR-31 in ESCC
cell lines. Statistical analysis was done by ANOVA. (B) SOX4, EZH2, EZH1 and HDAC3 expression in primary esophageal squamous cell carcinomas, ESCC,
compared to adjacent normal tissues (Geo dataset GSE20347). (C) SOX4, EZH2, EZH1 and HDAC3 expression in Barrett’s Esophagus lesions and primary
esophageal adenocarcinoma tumors, EAC, compared to adjacent normal tissues (Geo dataset GSE13898). (D) Model depicting reciprocal inhibition of
miR-31 and SOX4, EZH2 and HDAC3.
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Migration and Invasion assays were performed as previ-
ously described [52]. Migrating or invading cells were then
photographed using the Zeiss Axioskop Plus or eVos
microscope and quantified with ImageJ software.
Colony formation assay
For clonogenic assay, 500 transfected cells were seeded
in six-well plates and maintained in complete medium
for 2 weeks. Colonies were fixed with ice-cold methanol
and stained with crystal violet. Colonies were photo-
graphed and counted using GelCount (Oxford Optronix).
Western blot analysis
Western blot was performed as previously described [52].
Immunoprecipitation (IP)
Cells were collected and lysed in IP lysis buffer (150 mM
NaCL, 50 mM Tris pH8, 1% Triton X-100, 1% NP-40) sup-
plemented with protease and phosphatase inhibitors, incu-
bated on ice for 20 min, and cleared by centrifugation at
13,200 rpm at 4 C for 20 min. Total protein lysate (500 μg)
was immunoprecipitated with the agarose-immobilized
antibody (6 μg of anti-SOX4, EZH2, HDAC3 or isotype
control antibodies) and incubated overnight at 4°C. Im-
mune complexes were eluted from the agarose beads and
analyzed by SDS-PAGE followed by immunoblot analysis.
For co-IP in 293 T, cells were transfected with plasmids
using FuGene HD (Promega). Cells were collected 48 hours
post-transfection and analyzed as described above.
Chromatin Immunoprecipitation (ChIP)
The ChIP assays were adapted and performed according
to previous publications [53]. Briefly, cells were fixed
using 1% formaldehyde for 15 minutes and quenched
using 125 mM glycine for 5 minutes at room temperature.
After centrifugation the cell pellet was re-suspended in
the cell lysis buffer (150 mM NaCL, 50 mM Tris pH8, 1%
Triton X-100, 1% NP-40, 0.01% SDS, 1.2 mM EDTA
pH 8.0, 1 mM PMSF). Protein-bound chromatin was frag-
mented by sonication. Equal volumes of chromatin were
immunoprecipitated with anti-HDAC3, anti-SOX4, anti-
EZH2, anti-trimethyl-Histone H3 Lys27 or normal IgG as
a negative control (Millipore). Following extensive wash-
ing the immunoprecipitated DNA was treated with RNase
(Qiagen) for 30 min at 37°C and proteinase K (Roche) foran hour at 45°C. The DNA was eluted using 100 mM
NaHCO3 and 1% SDS and the crosslinks were reversed
using 300 mM NaCl at 65°C for 16 hours. Immunopreci-
pitated DNA and whole cell extract DNA were purified by
Qiaquick PCR purification kit (Qiagen). The purified
DNA was amplified by real-time quantitative PCR with
Qiagen QuantiTech SYBR Green PCR master mix and an-
alyzed for enrichment. Real-time qPCR amplification was
performed with Applied Biosystems StepOnePlus real
time PCR system.
Primers used as described in Lin et al. [44]: -1,000bp
forward: CCGATGACCTAGCCAGAAGT, reverse: CC
CCACCCTTCAACTCGTAG; -500 bp, forward: TATC
CTCAACCCTCCGTGTC, reverse: CATACACCTGAA
GGGGCAGT; +500 bp, forward: CAATTTTGGCCC
AGGAGATA, reverse: TTTCCGGGGACCTCTAGTT
T; +42,500 bp, forward: TGGCCTATTTGCTGTTCT
AATGAC, reverse: GCAAGCCAACCCCAACA; +45,000
bp, forward: AATGGGCCCTGCATTCTCT, reverse: AA
AACCCACACCCTCACCAC; +47,500 bp, forward: CAT
CTTCAAAAGCGGACACTCT, reverse: ACAATACATA
GCAGGACAGGAAG; MYT, forward: AGGCACCTTC
TGTTGGCCGA, reverse: AGGCAGCTGCCTCCCGTA
CA; GAPDH, forward: CGGCTACTAGCGGTTTTACG,
reverse: AAGAAGATGCGGCTGACTGT.
Dataset analysis
Datasets made publicly available from GEO Datasets
(http://www.ncbi.nlm.nih.gov/gds/). The collected infor-
mation from each dataset was analyzed and visualized in
Prism version 6.00 for Mac (GraphPad software, La Jolla,
California).
Statistical analysis
Each experiment was repeated at least three times. Nu-
merical data are presented as mean ± standard deviation.
The differences between two groups were analyzed using
a Student’s t-test (two-tailed) or two-way ANOVA. Differ-
ences were considered statistically significant at p < 0.05.
All statistical analysis was performed on GraphPad Prism
6.0c software (La Jolla, CA).
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